Mediator modulation therapy of severe sepsis and septic shock: Does it work?

被引：33
作者：
Dellinger, RP [1 ]
Parrillo, JE
机构：
[1] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Cooper Hosp, Dept Med,Sect Crit Care Med, Camden, NJ 08103 USA
[2] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Cooper Hosp,Cooper Heart Inst, Dept Med,Div Cardiovasc Dis & Crit Care Med, Camden, NJ 08103 USA
来源：
CRITICAL CARE MEDICINE | 2004年 / 32卷 / 01期
关键词：
D O I：
10.1097/01.CCM.0000105423.06091.8E
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：282 / 286
页数：5
相关论文
共 50 条
  • [1] EFFICACY AND SAFETY OF MONOCLONAL-ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA IN PATIENTS WITH SEPSIS SYNDROME - A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL-TRIAL
    ABRAHAM, E
    WUNDERINK, R
    SILVERMAN, H
    PERL, TM
    NASRAWAY, S
    LEVY, H
    BONE, R
    WENZEL, RP
    BALK, R
    ALLRED, R
    PENNINGTON, JE
    WHERRY, JC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (12): : 934 - 941
  • [2] Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis -: A randomized controlled trial
    Abraham, E
    Reinhart, K
    Opal, S
    Demeyer, I
    Doig, C
    Rodriguez, AL
    Beale, R
    Svoboda, P
    Laterre, PF
    Simon, S
    Light, B
    Spapen, H
    Stone, J
    Seibert, A
    Peckelsen, C
    De Deyne, C
    Postier, R
    Pettilä, V
    Sprung, CL
    Artigas, A
    Percell, SR
    Shu, V
    Zwingelstein, C
    Tobias, J
    Poole, L
    Stolzenbach, JC
    Creasey, AA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (02): : 238 - 247
  • [3] p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock - A randomized controlled multicenter trial
    Abraham, E
    Glauser, MP
    Butler, T
    Garbino, J
    Gelmont, D
    Laterre, PF
    Kudsk, K
    Bruining, HA
    Otto, C
    Tobin, E
    Zwingelstein, C
    Lesslauer, W
    Leighton, A
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (19): : 1531 - 1538
  • [4] Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients
    Abraham, E
    Laterre, PF
    Garbino, J
    Pingleton, S
    Butler, T
    Dugernier, T
    Margolis, B
    Kudsk, K
    Zimmerli, W
    Anderson, P
    Reynaert, M
    Lew, D
    Lesslauer, W
    Passe, S
    Cooper, P
    Burdeska, A
    Modi, M
    Leighton, A
    Salgo, M
    Van der Auwera, P
    [J]. CRITICAL CARE MEDICINE, 2001, 29 (03) : 503 - 510
  • [5] Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram-negative sepsis
    Albertson, TE
    Panacek, EA
    MacArthur, RD
    Johnson, SB
    Benjamin, E
    Matuschak, GM
    Zaloga, G
    Maki, D
    Silverstein, J
    Tobias, JK
    Haenftling, K
    Black, G
    Cowens, JW
    [J]. CRITICAL CARE MEDICINE, 2003, 31 (02) : 419 - 427
  • [6] Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock
    Annane, D
    Sébille, V
    Charpentier, C
    Bollaert, PE
    François, B
    Korach, JM
    Capellier, G
    Cohen, Y
    Azoulay, E
    Troché, G
    Chaumet-Riffaut, P
    Bellissant, E
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (07): : 862 - 871
  • [7] Administration of the nitric oxide synthase inhibitor NG-Methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis:: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002)
    Bakker, J
    Grover, R
    McLuckie, A
    Holzapfel, L
    Andersson, J
    Lodato, R
    Watson, D
    Grossman, S
    Donaldson, J
    Takala, J
    [J]. CRITICAL CARE MEDICINE, 2004, 32 (01) : 1 - 12
  • [8] The effects of ibuprofen on the physiology and survival of patients with sepsis
    Bernard, GR
    Wheeler, AP
    Russell, JA
    Schein, R
    Summer, WR
    Steinberg, KP
    Fulkerson, WJ
    Wright, PE
    Christman, BW
    Dupont, WD
    Higgins, SB
    Swindell, BB
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (13) : 912 - 918
  • [9] Efficacy and safety of recombinant human activated protein C for severe sepsis.
    Bernard, GR
    Vincent, JL
    Laterre, P
    LaRosa, SP
    Dhainaut, JF
    Lopez-Rodriguez, A
    Steingrub, JS
    Garber, GE
    Helterbrand, JD
    Ely, EW
    Fisher, CJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) : 699 - 709
  • [10] Role of nitric oxide in inflammatory conditions
    Blantz, RC
    Munger, K
    [J]. NEPHRON, 2002, 90 (04): : 373 - 378
12345